Literature DB >> 27002801

Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD.

Aliya F Gulamhusein1, John E Eaton2, James H Tabibian2, Elizabeth J Atkinson3, Brian D Juran1, Konstantinos N Lazaridis1.   

Abstract

OBJECTIVES: Primary sclerosing cholangitis (PSC) often coexists with inflammatory bowel disease (IBD) and can be complicated by cholangiocarcinoma (CCA), a lethal malignancy for which reliable predictors remain unknown. We aimed to characterize the influence of colectomy and IBD duration on risk of CCA in patients with PSC-IBD.
METHODS: A retrospective review of patients with PSC-IBD seen at the Mayo Clinic, Rochester, between January 2005 and May 2013 was performed. The primary outcome was time to development of CCA and our goal was to determine whether the risk differed between patients with and without colectomy. Risk factors were assessed using univariable and multivariable Cox proportional hazard models where colectomy, IBD disease duration, and development of advanced liver disease were treated as time-dependent covariates.
RESULTS: A total of 399 patients with PSC-IBD were included in the study, of whom 137 had a colectomy and 123 patients developed CCA. Age-adjusted univariate Cox proportional hazard models demonstrated that colectomy (hazard ratio (HR) 1.53, 95% confidence interval (CI) 1.05-2.22, P=0.02) and duration of IBD (HR 1.37, 95% CI 1.15-1.63, P<0.01) were associated with an increased risk of CCA, and colonic neoplasia (HR 1.52, 95% CI 0.97-2.37, P=0.06) and colectomy for colonic neoplasia (HR 1.62, 95% CI 1.01-2.61, P=0.05) approached significance. Among patients with a history of colectomy, colonic neoplasia as the indication for surgery was associated with a particularly increased risk of CCA (HR 2.91, 95% CI 1.24-6.84, P=0.01) compared with medically refractory disease. On multivariate analysis, duration of IBD remained significantly associated with CCA (HR 1.33, 95% CI 1.11-1.60, P<0.01). The influence of IBD duration on CCA risk was not modified after colectomy (P=0.69).
CONCLUSIONS: Prolonged duration of IBD is associated with an increased risk of CCA in patients with PSC-IBD, and colectomy itself does not modify this risk. These findings identify a subset of patients who are at high risk of this lethal complication and in need of close surveillance.

Entities:  

Mesh:

Year:  2016        PMID: 27002801      PMCID: PMC5027894          DOI: 10.1038/ajg.2016.55

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  27 in total

1.  Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease.

Authors:  Kirsten Boonstra; Karel J van Erpecum; Karin M J van Nieuwkerk; Joost P H Drenth; Alexander C Poen; Ben J M Witteman; Hans A R E Tuynman; Ulrich Beuers; Cyriel Y Ponsioen
Journal:  Inflamm Bowel Dis       Date:  2012-03-08       Impact factor: 5.325

2.  Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.

Authors:  K M Boberg; A Bergquist; S Mitchell; A Pares; F Rosina; U Broomé; R Chapman; O Fausa; T Egeland; G Rocca; E Schrumpf
Journal:  Scand J Gastroenterol       Date:  2002-10       Impact factor: 2.423

3.  Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis.

Authors:  U Broomé; R Löfberg; K Lundqvist; B Veress
Journal:  Dis Colon Rectum       Date:  1995-12       Impact factor: 4.585

4.  Primary sclerosing cholangitis: findings on cholangiography and pancreatography.

Authors:  R L MacCarty; N F LaRusso; R H Wiesner; J Ludwig
Journal:  Radiology       Date:  1983-10       Impact factor: 11.105

Review 5.  Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease.

Authors:  J Torres; G Pineton de Chambrun; S Itzkowitz; D B Sachar; J-F Colombel
Journal:  Aliment Pharmacol Ther       Date:  2011-06-22       Impact factor: 8.171

6.  Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential.

Authors:  U Broomé; R Löfberg; B Veress; L S Eriksson
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

7.  Metabolism of the colonic mucosa in patients with inflammatory bowel diseases: an in vitro proton magnetic resonance spectroscopy study.

Authors:  Krithika Balasubramanian; Sandeep Kumar; Rajeev R Singh; Uma Sharma; Vineet Ahuja; Govind K Makharia; Naranamangalam R Jagannathan
Journal:  Magn Reson Imaging       Date:  2008-07-03       Impact factor: 2.546

Review 8.  Primary sclerosing cholangitis.

Authors:  Gideon M Hirschfield; Tom H Karlsen; Keith D Lindor; David H Adams
Journal:  Lancet       Date:  2013-06-28       Impact factor: 79.321

9.  Fecal and stomal bile acid composition after ileostomy or ileoanal anastomosis in patients with chronic ulcerative colitis and adenomatosis coli.

Authors:  H Natori; J Utsunomiya; T Yamamura; Y Benno; K Uchida
Journal:  Gastroenterology       Date:  1992-04       Impact factor: 22.682

10.  Imaging of intrahepatic cholangiocarcinoma: 1. Peripheral cholangiocarcinoma.

Authors:  P Soyer; D A Bluemke; R Reichle; P S Calhoun; D F Bliss; A Scherrer; E K Fishman
Journal:  AJR Am J Roentgenol       Date:  1995-12       Impact factor: 3.959

View more
  28 in total

1.  Metastatic Epstein-Barr Virus-Positive Lymphoepithelioma-Like Cholangiocarcinoma in a Young Man With Ulcerative Colitis.

Authors:  Nicholas Y Tan; Shounak Majumder; Meera Sridharan; Sarah E Kerr; Rondell P Graham; Karthik Ravi
Journal:  Am J Gastroenterol       Date:  2017-03       Impact factor: 10.864

2.  Impact of Crohn's Disease Duration on the Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis.

Authors:  De-Jun Cui; Xun Zhao; Mei Hu
Journal:  Am J Gastroenterol       Date:  2017-01       Impact factor: 10.864

3.  Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.

Authors:  Tobias J Weismüller; Palak J Trivedi; Annika Bergquist; Mohamad Imam; Henrike Lenzen; Cyriel Y Ponsioen; Kristian Holm; Daniel Gotthardt; Martti A Färkkilä; Hanns-Ulrich Marschall; Douglas Thorburn; Rinse K Weersma; Johan Fevery; Tobias Mueller; Olivier Chazouillères; Kornelius Schulze; Konstantinos N Lazaridis; Sven Almer; Stephen P Pereira; Cynthia Levy; Andrew Mason; Sigrid Naess; Christopher L Bowlus; Annarosa Floreani; Emina Halilbasic; Kidist K Yimam; Piotr Milkiewicz; Ulrich Beuers; Dep K Huynh; Albert Pares; Christine N Manser; George N Dalekos; Bertus Eksteen; Pietro Invernizzi; Christoph P Berg; Gabi I Kirchner; Christoph Sarrazin; Vincent Zimmer; Luca Fabris; Felix Braun; Marco Marzioni; Brian D Juran; Karouk Said; Christian Rupp; Kalle Jokelainen; Maria Benito de Valle; Francesca Saffioti; Angela Cheung; Michael Trauner; Christoph Schramm; Roger W Chapman; Tom H Karlsen; Erik Schrumpf; Christian P Strassburg; Michael P Manns; Keith D Lindor; Gideon M Hirschfield; Bettina E Hansen; Kirsten M Boberg
Journal:  Gastroenterology       Date:  2017-03-06       Impact factor: 22.682

Review 4.  Cholangiocarcinoma: novel therapeutic targets.

Authors:  Keisaku Sato; Shannon Glaser; Domenico Alvaro; Fanyin Meng; Heather Francis; Gianfranco Alpini
Journal:  Expert Opin Ther Targets       Date:  2020-02-26       Impact factor: 6.902

5.  Primary sclerosing cholangitis: A review and update.

Authors:  James H Tabibian; Christopher L Bowlus
Journal:  Liver Res       Date:  2017-12

6.  Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver.

Authors:  Aldo J Montano-Loza; Jessica R Allegretti; Angela Cheung; Maryam Ebadi; David Jones; Nanda Kerkar; Cynthia Levy; Sumera Rizvi; John M Vierling; Fernando Alvarez; Wayne Bai; Susan Gilmour; Aliya Gulamhusein; Orlee Guttman; Bettina E Hansen; Sonya MacParland; Andrew Mason; Fernanda Onofrio; Pere Santamaria; Ashley Stueck; Mark Swain; Catherine Vincent; Amanda Ricciuto; Gideon Hirschfield
Journal:  Can Liver J       Date:  2021-11-11

7.  Surveillance for Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis: Effective and Justified?

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Clin Liver Dis (Hoboken)       Date:  2016-08-29

8.  Primary Sclerosing Cholangitis, Part 2: Cancer Risk, Prevention, and Surveillance.

Authors:  James H Tabibian; Ahmad H Ali; Keith D Lindor
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-07

9.  Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment.

Authors:  James H Tabibian; Ahmad H Ali; Keith D Lindor
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-05

Review 10.  The changing faces of cholangitis.

Authors:  Sum P Lee; Joseph R Roberts; Rahul Kuver
Journal:  F1000Res       Date:  2016-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.